Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile

Simple item page
dc.contributor.authorJakhar, Kalpna
dc.contributor.authorVaishnavi, Swetha
dc.contributor.authorKaur, Prabhsimran
dc.contributor.authorSingh, Paramdeep
dc.contributor.authorMunshi, Anjana
dc.date.accessioned2024-01-21T10:54:09Z
dc.date.accessioned2024-08-14T07:40:53Z
dc.date.available2024-01-21T10:54:09Z
dc.date.available2024-08-14T07:40:53Z
dc.date.issued2022-10-28T00:00:00
dc.description.abstractType 2 Diabetes mellitus (T2DM) is a multifactorial metabolic disorder also known as a silent killer disease. Macrovascular and microvascular complications associated with diabetes worsen the condition leading to higher comorbidity and mortality rate. Currently, available treatment strategies for diabetes include biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, insulin and its analogs, DPP-4 (dipeptidyl-peptidase-4) inhibitors, SGLT-2 inhibitors, and Glucagon Like Peptide-1 receptor agonists (GLP-1RAs). Synthetic agonists of GLP-1 hormone, GLP-1RAs are an emerging class of anti-diabetic drugs which target the pathophysiology of diabetes through various mechanisms and at multiple sites. They promote insulin secretion from beta cells, and the proliferation of beta cells inhibits glucagon secretion, delays gastric emptying and induces satiety. However, treatment is reported to be associated with inter-individual variations and adverse drug reactions, which are also influenced by genetic variations. There have been a few pharmacogenetic studies have been carried out on this drug class. This review discusses all the available GLP-1RAs, their pharmacokinetics, pharmacodynamics and genetic variation affecting the inter-individual variation. � 2022 Elsevier B.V.en_US
dc.identifier.doi10.1016/j.ejphar.2022.175356
dc.identifier.issn142999
dc.identifier.urihttp://10.2.3.109/handle/32116/4228
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0014299922006173
dc.language.isoen_USen_US
dc.publisherElsevier B.V.en_US
dc.subjectGLP-1RAsen_US
dc.subjectOral-antidiabetic drugsen_US
dc.subjectPharmacodynamicsen_US
dc.subjectPharmacogenomicsen_US
dc.subjectPharmacokineticsen_US
dc.titlePharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profileen_US
dc.title.journalEuropean Journal of Pharmacologyen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Human Genetics And Molecular Medicine - Research Publications